382 related articles for article (PubMed ID: 37629010)
21. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
[TBL] [Abstract][Full Text] [Related]
22. Targeting the glucagon receptor family for diabetes and obesity therapy.
Cho YM; Merchant CE; Kieffer TJ
Pharmacol Ther; 2012 Sep; 135(3):247-78. PubMed ID: 22659620
[TBL] [Abstract][Full Text] [Related]
23. Advances in non-peptide glucagon receptor antagonists.
Madsen P; Brand CL; Holst JJ; Knudsen B
Curr Pharm Des; 1999 Sep; 5(9):683-691. PubMed ID: 10495358
[TBL] [Abstract][Full Text] [Related]
24. Paracrine regulation of somatostatin secretion by insulin and glucagon in mouse pancreatic islets.
Svendsen B; Holst JJ
Diabetologia; 2021 Jan; 64(1):142-151. PubMed ID: 33043402
[TBL] [Abstract][Full Text] [Related]
25. Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction.
McLean BA; Wong CK; Kabir MG; Drucker DJ
Mol Metab; 2022 Dec; 66():101641. PubMed ID: 36396031
[TBL] [Abstract][Full Text] [Related]
26. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-like peptide-1, a new hormone of the entero-insular axis.
Orskov C
Diabetologia; 1992 Aug; 35(8):701-11. PubMed ID: 1324859
[TBL] [Abstract][Full Text] [Related]
28. Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.
Wohlfart P; Linz W; Hübschle T; Linz D; Huber J; Hess S; Crowther D; Werner U; Ruetten H
J Transl Med; 2013 Mar; 11():84. PubMed ID: 23537041
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes.
Monji A; Mitsui T; Bando YK; Aoyama M; Shigeta T; Murohara T
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(3):H295-304. PubMed ID: 23709595
[TBL] [Abstract][Full Text] [Related]
30. A new GLP1, GIP and glucagon receptor triagonist.
Starling S
Nat Rev Endocrinol; 2022 Mar; 18(3):135. PubMed ID: 34992235
[No Abstract] [Full Text] [Related]
31. Glucagon-like peptide 1: continued advances, new targets and expanding promise as a model therapeutic.
Aulinger B; D'Alessio D
Curr Opin Endocrinol Diabetes Obes; 2007 Feb; 14(1):68-73. PubMed ID: 17940423
[TBL] [Abstract][Full Text] [Related]
32. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling.
Lovshin J; Estall J; Yusta B; Brown TJ; Drucker DJ
J Biol Chem; 2001 Jun; 276(24):21489-99. PubMed ID: 11262390
[TBL] [Abstract][Full Text] [Related]
33. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Ban K; Kim KH; Cho CK; Sauvé M; Diamandis EP; Backx PH; Drucker DJ; Husain M
Endocrinology; 2010 Apr; 151(4):1520-31. PubMed ID: 20172966
[TBL] [Abstract][Full Text] [Related]
34. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.
Thorkildsen C; Neve S; Larsen BD; Meier E; Petersen JS
J Pharmacol Exp Ther; 2003 Nov; 307(2):490-6. PubMed ID: 12975499
[TBL] [Abstract][Full Text] [Related]
35. GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr
Patel A; Yusta B; Matthews D; Charron MJ; Seeley RJ; Drucker DJ
Mol Metab; 2018 Oct; 16():45-54. PubMed ID: 29937214
[TBL] [Abstract][Full Text] [Related]
36. Localization and regulation of glucagon receptors in the chick eye and preproglucagon and glucagon receptor expression in the mouse eye.
Feldkaemper MP; Burkhardt E; Schaeffel F
Exp Eye Res; 2004 Sep; 79(3):321-9. PubMed ID: 15336494
[TBL] [Abstract][Full Text] [Related]
37. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
38. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
Tai J; Liu W; Li Y; Li L; Hölscher C
Brain Res; 2018 Jan; 1678():64-74. PubMed ID: 29050859
[TBL] [Abstract][Full Text] [Related]
39. Glucagon stimulates exocytosis in mouse and rat pancreatic alpha-cells by binding to glucagon receptors.
Ma X; Zhang Y; Gromada J; Sewing S; Berggren PO; Buschard K; Salehi A; Vikman J; Rorsman P; Eliasson L
Mol Endocrinol; 2005 Jan; 19(1):198-212. PubMed ID: 15459251
[TBL] [Abstract][Full Text] [Related]
40. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
